- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Report highlights need for improved management of CDI in IBD patients
11 April 2016 • Author: Victoria White, Digital Content Producer
Results from an international consensus project involving a multidisciplinary group of clinicians highlight the need for improved management of Clostridium difficile infection (CDI) in inflammatory bowel disease (IBD) patients.
A current lack of data on outcomes in patients with IBD who have CDI means that appropriate choice of treatment strategy can be unclear. The consensus examines the issues impacting clinical professionals working with CDI and aims to understand the perceptions and attitudes of key stakeholders regarding best practice in the management of CDI in patients with IBD.
CDI is associated with high-mortality and cost burden. It causes or contributes to death in 2 out of 5 people who die within 3 months of diagnosis and patients who acquire CDI are estimated to stay in hospital for an extra one to three weeks at an additional cost of up to €14,000 per patient. Research has shown that IBD patients with co-existent CDI are hospitalised for substantially longer, with a median length of stay of 26 days compared with just 5 days for patients with IBD alone. Overall, CDI is estimated to cost the EU €3 billion per annum and this cost is expected to almost double over the next four decades.
“We know that CDI has important consequences for patients and healthcare systems, including excess morbidity, mortality and length of hospitalisation. These consequences are most pronounced in vulnerable patients, including those with inflammatory bowel disease”, commented study author Professor Mark Wilcox, Professor of Medical Microbiology, Leeds Teaching Hospitals & University of Leeds.
Recommendations to improve management of CDI in IBD patients
Based on the consensus scores of 426 international healthcare professionals, including infectious disease specialists, microbiologists, and gastroenterologists, recommendations have been suggested to further develop and improve the management of CDI in patients with IBD:
- The need for a treatment strategy for CDI in IBD that is driven by risk factors for poor outcome rather than one solely defined by severity of disease;
- The need for clarity regarding clinical definitions of recurrent CDI and recurrent CDI in IBD patients;
- The utility of a common approach to CDI in IBD in helping to reduce variance in clinical practice between specialties and the need for clinicians to be familiar with the role and responsibilities of other specialties in managing CDI in IBD;
- The need for higher quality evidence to inform future CDI guidelines;
- The need for further data to define the place of faecal microbiota transplant in CDI patients with IBD;
- Recognition of CDI risk factors was low amongst clinicians, indicating the need for a model for scoring symptom severity.
Clinicians were asked to rate their agreement with 27 statements. Statements were submitted to respondents at conferences and congresses and, based on the resultant consensus scoring, recommendations were developed. Levels of agreement exceeded the 75% threshold for consensus for 17 out of the 27 statements, indicating strong support for the majority. Differences were observed between the perceptions of microbiologists and gastroenterologists as well as between countries.
“The survey showed that members from all participating medical disciplines equally recognise the importance of infections with Clostridium difficile as critical events in the course of inflammatory bowel disease. It was astonishing to find, however, that the diagnostic and treatment strategies vary significantly between different specialists”, said Professor Dr med. Andreas Stallmach, Department of Internal Medicine IV, Jena University Hospital. “The results of this study underline that we urgently need interdisciplinary controlled studies aiming to optimise and harmonise treatment strategies for C. difficile in patients with inflammatory bowel disease.”
The results of the project were been presented today at 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2016.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics